Vigil Neuroscience Inc

Vigil Neuroscience — JP Morgan Healthcare Conference 2024

31 slides from Vigil Neuroscience's conference presentation, Jan 11, 2024

  1. Slide 1: JP Morgan Healthcare Conference

    Slide 1: JP Morgan Healthcare Conference

    JP Morgan Healthcare Conference January 11, 2024 © Vigil Neuroscience, Inc. 2024. All rights reserved. Ivana Magovčević-Liebisch, PhD, JD President & Chief Executive Officer Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements,” which are made pursuant to the safe harbor provisions of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact may be d

  3. Slide 3: Vigil Neuroscience: A Clinical-Stage Microglia-Focused Therapeutics Company

    Slide 3: Vigil Neuroscience: A Clinical-Stage Microglia-Focused Therapeutics Company

    Vigil Neuroscience: A Clinical-Stage Microglia-Focused Therapeutics Company Focused on treating rare and common neurodegenerative diseases by restoring vigilance of microglia, the brain’s sentinel immune cells Precision-based strategy for developing microglia therapeutics Only company known to have

  4. Slide 4: Restoring Microglia with TREM2 as a Therapeutic Target

    Slide 4: Restoring Microglia with TREM2 as a Therapeutic Target

    Restoring Microglia with TREM2 as a Therapeutic Target © Vigil Neuroscience, Inc. 2024. All rights reserved. Microglia sense and respond to damage signals and coordinate signal-specific downstream responses Microglial dysfunction is associated with rare and common neurodegenerative diseases TREM2 is

  5. Slide 5: Vigil's Precision Medicine Strategy to Target Broad Range of Neurodegenerative Diseases

    Slide 5: Vigil's Precision Medicine Strategy to Target Broad Range of Neurodegenerative Diseases

    Vigil’s Precision Medicine Strategy to Target Broad Range of Neurodegenerative Diseases First Indication Rare Microgliopathy (ALSP) Data Driven Expansion in Other Rare Microgliopathies Pipeline Candidates for Genetically Defined Subpopulations in Common Indications (AD) Further Expansion into Broade

  6. Slide 6: Vigil TREM2 Agonists: Differentiated Strategy & Multiple Modalities

    Slide 6: Vigil TREM2 Agonists: Differentiated Strategy & Multiple Modalities

    Vigil TREM2 Agonists: Differentiated Strategy & Multiple Modalities Iluzanebart (VGL101): TREM2 mAb in development for ALSP VG-3927: Small Molecule TREM2 Agonist in development for AD ONLY targeted drug candidate in clinical development for ALSP 1st & ONLY TREM2 small molecule agonist in clinical de

  7. Slide 7: Building a Robust Pipeline in Rare & Common Neurodegenerative Diseases

    Slide 7: Building a Robust Pipeline in Rare & Common Neurodegenerative Diseases

    Building a Robust Pipeline in Rare & Common Neurodegenerative Diseases Vigil has exclusive rights to all programs Alzheimer’s Disease Iluzanebart (VGL101): Fully Human Monoclonal Antibody Healthy Volunteer Phase 1 Trial1 (Completed) Healthy Volunteer VG-3927: Oral Small Molecule TREM2 Agonist Discov

  8. Slide 8: Iluzanebart (VGL101) Antibody TREM2 Agonist for Treatment of ALSP

    Slide 8: Iluzanebart (VGL101) Antibody TREM2 Agonist for Treatment of ALSP

    Iluzanebart (VGL101) Antibody TREM2 Agonist for Treatment of ALSP © Vigil Neuroscience, Inc. 2024. All rights reserved. Iluzanebart (VGL101) is an investigational therapy and has not been reviewed or approved by any regulatory authority

  9. Slide 9: ALSP: A Genetically-linked Microgliopathy with Significant Unmet Need

    Slide 9: ALSP: A Genetically-linked Microgliopathy with Significant Unmet Need

    Epidemiology 10% adult-onset leukodystrophies: Including ~10K patients in U.S. & ~15K patients in EU27+UK Monogenic Disease Autosomal dominant CSF1R gene mutations Clinical Phenotype Average age of onset in mid-40s Cognitive, neuropsychiatric and motor symptoms Commonly misdiagnosed Rapid Progressio

  10. Slide 10: Validation: Iluzanebart Compensation of CSF1R Signaling Defect

    Slide 10: Validation: Iluzanebart Compensation of CSF1R Signaling Defect

    Validation: Iluzanebart Compensation of CSF1R Signaling Defect Iluzanebart Rescues Microglial Deficiency Caused by CSF1R Mutations © Vigil Neuroscience, Inc. 2024. All rights reserved. IBA-staining; red arrows denote microglia - Berdowski et al. Acta Neuropath 2022 TREM2 Agonism via Iluzanebart Phar

  11. Slide 11: Proof of target engagement and pharmacological activity in healthy volunteers

    Slide 11: Proof of target engagement and pharmacological activity in healthy volunteers

    Proof of target engagement and pharmacological activity in healthy volunteers 1st antibody to report durable effect on microglial activity biomarkers in clinical setting Summary of Iluzanebart Phase 1 Data in Healthy Volunteers SAD: single ascending dose; MAD: multiple ascending dose; PK: pharmacoki

  12. Slide 12: ILLUMINATE: First Natural History Study in ALSP

    Slide 12: ILLUMINATE: First Natural History Study in ALSP

    ILLUMINATE: First Natural History Study in ALSP ILLUMINATE: NCT05020743 © Vigil Neuroscience, Inc. 2024. All rights reserved. Ongoing natural history study of ALSP patients with CSF1R gene mutation Enrolling up to 50 subjects globally Observation period: 24 months To characterize MRI & CSF biomarker

  13. Slide 13: Baseline Fluid Biomarker Levels Altered in ALSP

    Slide 13: Baseline Fluid Biomarker Levels Altered in ALSP

    Baseline Fluid Biomarker Levels Altered in ALSP NfL levels highly elevated in symptomatic sTREM2 levels similar across all populations sCSF1R levels significantly reduced in prodromal and symptomatic sTREM2 concentration (pg/ml) 0 1000 2000 3000 4000 51 4 7 Healthy Prodromal Symptomatic sCSF1R conce

  14. Slide 14: MRI Biomarkers of Disease Progression Precede Cognitive Decline

    Slide 14: MRI Biomarkers of Disease Progression Precede Cognitive Decline

    Gray Matter Volume Change from Baseline at Month 12 Montreal Cognitive Assessment (MoCA)* MoCA Change from Baseline Prodromal (11) Symptomatic (6) Cognitive Worsening 2 1 0 1 -2 -3 -4 MRI Biomarkers of Disease Progression Precede Cognitive Decline Plots are Mean ± SE * Montreal Cognitive Assessment:

  15. Slide 15: MRI Biomarkers of Disease Progression Correlate with Cognitive Decline

    Slide 15: MRI Biomarkers of Disease Progression Correlate with Cognitive Decline

    MRI Biomarkers of Disease Progression Correlate with Cognitive Decline Worsening Worsening © Vigil Neuroscience, Inc. 2024. All rights reserved. Worsening Worsening Ventricular/Gray matter volume changes correlate with MoCA changes at 12 Months Prodromal Symptomatic Ventricular Volume Changes (mL) M

  16. Slide 16: Evaluating Iluzanebart for ALSP in IGNITE Phase 2 Open-Label Proof-of-Concept Trial

    Slide 16: Evaluating Iluzanebart for ALSP in IGNITE Phase 2 Open-Label Proof-of-Concept Trial

    Evaluating Iluzanebart for ALSP in IGNITE Phase 2 Open-Label Proof-of-Concept Trial © Vigil Neuroscience, Inc. 2024. All rights reserved. Follow up Trial Population Patients with symptomatic ALSP related to CSF1R gene mutation Trial Design Open-label, ~15 patients Treatment Duration 12 months (with

  17. Slide 17: IGNITE Phase 2 Interim Readout: Favorable Safety & Tolerability Profile

    Slide 17: IGNITE Phase 2 Interim Readout: Favorable Safety & Tolerability Profile

    IGNITE Phase 2 Interim Readout: Favorable Safety & Tolerability Profile Safety data summary Summary of Safety Outcomes (N=6)a Patients with TEAEs Any AE, n (%) 4 (66.7) Treatment-related AEs, n (%)b 2 (33.3) Mildc 2 (33.3) Moderatec 1 (16.7) Severe 0 Treatment-related AEs occurring in ≥2 participant

  18. Slide 18: Emerging Patient Segments in IGNITE Phase 2 Interim Readout

    Slide 18: Emerging Patient Segments in IGNITE Phase 2 Interim Readout

    Emerging Patient Segments in IGNITE Phase 2 Interim Readout NfL significantly higher than age-normal range MoCA <26 Significant neurodegeneration with cognitive impairment as one of ALSP symptoms NfL higher than age-normal range MoCA >26 Evidence of neurodegeneration Have other ALSP symptoms except

  19. Slide 19: IGNITE Phase 2: Summary of Biomarker Changes

    Slide 19: IGNITE Phase 2: Summary of Biomarker Changes

    Progressive Disease Cognitively Normal Potentially Converting IGNITE Phase 2: Summary of Biomarker Changes 6-month interim analysis1 Patient1 Baseline NfL (pg/mL) Baseline MoCA ΔMRI Venticular2 ΔMRI Gray Matter2 ΔsCSF1R CSF3 ΔNfL Serum4 VGL101 Impact Based on Biomarker Changes A 80 17 Slowing progre

  20. Slide 20: Positioning Iluzanebart for Potential Accelerated Development Pathway

    Slide 20: Positioning Iluzanebart for Potential Accelerated Development Pathway

    Positioning Iluzanebart for Potential Accelerated Development Pathway Iluzanebart (VGL101) Target engagement with mechanistic link - iluzanebart increased sCSF1R levels (very low in untreated patients) Directionally supportive changes on MRI & NfL for iluzanebart in Ph2 MRI biomarkers correlating wi

  21. Slide 21: VG-3927 Small Molecule TREM2 Agonist for Treatment of Alzheimer's Disease

    Slide 21: VG-3927 Small Molecule TREM2 Agonist for Treatment of Alzheimer's Disease

    VG-3927 Small Molecule TREM2 Agonist for Treatment of Alzheimer’s Disease © Vigil Neuroscience, Inc. 2024. All rights reserved.

  22. Slide 22: Human Microglia Play a Central Role in Alzheimer's Disease

    Slide 22: Human Microglia Play a Central Role in Alzheimer's Disease

    Human Microglia Play a Central Role in Alzheimer’s Disease (AD) Loss of TREM2 Function Worsens Neurodegeneration in AD Models TREM2 Small Molecule Agonist: Broad Potential to Reduce AD Pathology via Oral Dosing AD risk variants impair microglia clustering around Aβ plaques TREM2 deficiency is associ

  23. Slide 23: VG-3927: First & Only Clinical-stage Small Molecule TREM2 Agonist

    Slide 23: VG-3927: First & Only Clinical-stage Small Molecule TREM2 Agonist

    Increased Versatility Improved Safety VG-3927: First & Only Clinical-stage Small Molecule TREM2 Agonist VG-3927 Potential Differentiation Small molecule optimal for future combination therapy & preventive paradigms Wider therapeutic window: synergy with natural damage ligands ARIA mitigation & manag

  24. Slide 24: VG-3927 Potentiates Signaling of Damage-associated Ligands

    Slide 24: VG-3927 Potentiates Signaling of Damage-associated Ligands

    VG-3927 Potentiates Signaling of Damage-associated Ligands Focusing Efficacy in Pathological Microenvironments Plaque-burdened AD State Potentiation of TREM2 Activation VG-3927 Sulfatide Alone VG-3927 Alone VG-3927 + Sulfatide TREM2 Activation © Vigil Neuroscience, Inc. 2024. All rights reserved. Su

  25. Slide 25: VG-3927 Protects Against Biomarkers of Inflammation-induced Neurodegeneration

    Slide 25: VG-3927 Protects Against Biomarkers of Inflammation-induced Neurodegeneration

    VG-3927 Protects Against Biomarkers of Inflammation-induced Neurodegeneration ANOVATreatment, p<0.05 VG-3927 Suppresses Extracellular NfL & Tau Accumulation in LPS Model TREM2 Agonism Activates Anti-inflammatory Benefit VG-3927 Neuro- inflammation Neurodeg Stimulus LPS/IFNy Neurodegeneration Extrace

  26. Slide 26: VG-3927 Reduces Aβ Pathology in Plaque-bearing Mice

    Slide 26: VG-3927 Reduces Aβ Pathology in Plaque-bearing Mice

    VG-3927 Reduces Aβ Pathology in Plaque-bearing Mice VG-3927 Effects in Humanized TREM2 AD Mouse Model VG-3927 dosing initiated at ~5 months (plaque deposition already ongoing) Trend toward reducing plaque area and insoluble Aβ Daily Dosing for 6 Weeks VG-3927 10mpk QD Effects following 6 weeks of or

  27. Slide 27: VG-3927: Early-Stage Clinical Strategy to De-Risk Development for AD

    Slide 27: VG-3927: Early-Stage Clinical Strategy to De-Risk Development for AD

    Ongoing Phase 1 SAD/MAD in healthy volunteers Exploring safety, tolerability, PK & PD PD biomarkers: sTREM2, sCSF1R & osteopontin Planned Phase 1b AD cohort Safety & tolerability PD in genetically-defined subpopulations (e.g., TREM2 variants) Identify AD subpopulation for future clinical trials Plan

  28. Slide 28: Corporate Overview

    Slide 28: Corporate Overview

    Corporate Overview © Vigil Neuroscience, Inc. 2024. All rights reserved.

  29. Slide 29: Achieved & Anticipated Milestones

    Slide 29: Achieved & Anticipated Milestones

    Achieved & Anticipated Milestones Report VG-3927 interim Phase 1 data in healthy volunteers Mid-2024 © Vigil Neuroscience, Inc. 2024. All rights reserved. Report full data analysis for Phase 1 trial with iluzanebart in healthy volunteers Oct 2023 Q4 2023 Begin Phase 1 dosing of VG-3927 in healthy vo

  30. Slide 30: Vigil is Well-positioned to Execute on Our Mission

    Slide 30: Vigil is Well-positioned to Execute on Our Mission

    Vigil is Well-positioned to Execute on Our Mission Our vision is a brighter tomorrow for people with devastating neurodegenerative diseases Microglial biology is rapidly becoming a new frontier for CNS drug discovery TREM2 deficiency leads to microglial dysfunction & drives neurodegeneration We are

  31. Slide 31: Thank You

    Slide 31: Thank You

    THANK YOU VIGILANT FOR YOU is a registered trademark of Vigil Neuroscience, Inc. VIGIL, VIGIL NEUROSCIENCE, VIGIL NEURO, and the VIGIL NEURO, ILLUMINATE and IGNITE logos are trademarks of Vigil Neuroscience, Inc. © Vigil Neuroscience, Inc. 2024. All rights reserved.

Source: SEC EDGAR · 8-K filed Jan 11, 2024

More decks from Vigil Neuroscience Inc